ID   HS3S5_HUMAN             Reviewed;         346 AA.
AC   Q8IZT8; A8K1J2; Q52LI2; Q8N285;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2003, sequence version 1.
DT   10-MAY-2017, entry version 128.
DE   RecName: Full=Heparan sulfate glucosamine 3-O-sulfotransferase 5;
DE            EC=2.8.2.23;
DE   AltName: Full=Heparan sulfate D-glucosaminyl 3-O-sulfotransferase 5;
DE            Short=3-OST-5;
DE            Short=Heparan sulfate 3-O-sulfotransferase 5;
DE            Short=h3-OST-5;
GN   Name=HS3ST5; Synonyms=3OST5, HS3OST5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, CHARACTERIZATION, AND
RP   FUNCTION IN HSV-1 ENTRY.
RC   TISSUE=Placenta;
RX   PubMed=12138164; DOI=10.1074/jbc.M204209200;
RA   Xia G., Chen J., Tiwari V., Ju W., Li J.-P., Malmstroem A., Shukla D.,
RA   Liu J.;
RT   "Heparan sulfate 3-O-sulfotransferase isoform 5 generates both an
RT   antithrombin-binding site and an entry receptor for herpes simplex
RT   virus, type 1.";
RL   J. Biol. Chem. 277:37912-37919(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Caudate nucleus, and Corpus callosum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   CHARACTERIZATION, AND TISSUE SPECIFICITY.
RX   PubMed=12740361; DOI=10.1074/jbc.M301861200;
RA   Mochizuki H., Yoshida K., Gotoh M., Sugioka S., Kikuchi N.,
RA   Kwon Y.-D., Tawada A., Maeyama K., Inaba N., Hiruma T., Kimata K.,
RA   Narimatsu H.;
RT   "Characterization of a heparan sulfate 3-O-sulfotransferase-5, an
RT   enzyme synthesizing a tetrasulfated disaccharide.";
RL   J. Biol. Chem. 278:26780-26787(2003).
RN   [6]
RP   CHARACTERIZATION.
RX   PubMed=15026143; DOI=10.1016/j.bbagen.2003.12.010;
RA   Duncan M.B., Chen J., Krise J.P., Liu J.;
RT   "The biosynthesis of anticoagulant heparan sulfate by the heparan
RT   sulfate 3-O-sulfotransferase isoform 5.";
RL   Biochim. Biophys. Acta 1671:34-43(2004).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 88-346 IN COMPLEX WITH
RP   ADENOSINE-3'-5'-DIPHOSPHATE, CATALYTIC ACTIVITY, AND MUTAGENESIS OF
RP   ARG-99; ARG-104; LYS-155; GLN-195; LYS-309 AND ARG-311.
RX   PubMed=18223645; DOI=10.1038/nchembio.66;
RA   Xu D., Moon A.F., Song D., Pedersen L.C., Liu J.;
RT   "Engineering sulfotransferases to modify heparan sulfate.";
RL   Nat. Chem. Biol. 4:200-202(2008).
CC   -!- FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl
CC       sulfate (PAPS) to catalyze the transfer of a sulfo group to
CC       position 3 of glucosamine residues in heparan. Catalyzes the rate
CC       limiting step in the biosynthesis of heparan sulfate (HSact). This
CC       modification is a crucial step in the biosynthesis of
CC       anticoagulant heparan sulfate as it completes the structure of the
CC       antithrombin pentasaccharide binding site. Also generates GlcUA-
CC       GlcNS or IdoUA-GlcNS and IdoUA2S-GlcNH2. The substrate-specific O-
CC       sulfation generates an enzyme-modified heparan sulfate which acts
CC       as a binding receptor to Herpes simplex virus-1 (HSV-1) and
CC       permits its entry. {ECO:0000269|PubMed:12138164}.
CC   -!- CATALYTIC ACTIVITY: 3'-phosphoadenylyl sulfate + [heparan
CC       sulfate]-glucosamine = adenosine 3',5'-bisphosphate + [heparan
CC       sulfate]-glucosamine 3-sulfate. {ECO:0000269|PubMed:18223645}.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane {ECO:0000305};
CC       Single-pass type II membrane protein {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in skeletal muscle and fetal
CC       brain, and also found in adult brain, spinal cord, cerebellum and
CC       colon. {ECO:0000269|PubMed:12138164, ECO:0000269|PubMed:12740361}.
CC   -!- SIMILARITY: Belongs to the sulfotransferase 1 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF503292; AAN37737.1; -; mRNA.
DR   EMBL; AK091074; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK289907; BAF82596.1; -; mRNA.
DR   EMBL; CH471051; EAW48251.1; -; Genomic_DNA.
DR   EMBL; BC093911; AAH93911.1; -; mRNA.
DR   EMBL; BC093913; AAH93913.1; -; mRNA.
DR   CCDS; CCDS34517.1; -.
DR   RefSeq; NP_705840.2; NM_153612.3.
DR   RefSeq; XP_006715442.1; XM_006715379.2.
DR   RefSeq; XP_011533890.1; XM_011535588.2.
DR   RefSeq; XP_016865959.1; XM_017010470.1.
DR   RefSeq; XP_016865960.1; XM_017010471.1.
DR   RefSeq; XP_016865961.1; XM_017010472.1.
DR   RefSeq; XP_016865962.1; XM_017010473.1.
DR   RefSeq; XP_016865963.1; XM_017010474.1.
DR   UniGene; Hs.645477; -.
DR   PDB; 3BD9; X-ray; 2.30 A; A=88-346.
DR   PDBsum; 3BD9; -.
DR   ProteinModelPortal; Q8IZT8; -.
DR   SMR; Q8IZT8; -.
DR   STRING; 9606.ENSP00000427888; -.
DR   iPTMnet; Q8IZT8; -.
DR   PhosphoSitePlus; Q8IZT8; -.
DR   BioMuta; HS3ST5; -.
DR   DMDM; 61214369; -.
DR   PaxDb; Q8IZT8; -.
DR   PRIDE; Q8IZT8; -.
DR   Ensembl; ENST00000312719; ENSP00000427888; ENSG00000249853.
DR   Ensembl; ENST00000411826; ENSP00000440332; ENSG00000249853.
DR   GeneID; 222537; -.
DR   KEGG; hsa:222537; -.
DR   UCSC; uc003pwg.4; human.
DR   CTD; 222537; -.
DR   DisGeNET; 222537; -.
DR   GeneCards; HS3ST5; -.
DR   HGNC; HGNC:19419; HS3ST5.
DR   HPA; HPA021823; -.
DR   HPA; HPA064677; -.
DR   MIM; 609407; gene.
DR   neXtProt; NX_Q8IZT8; -.
DR   OpenTargets; ENSG00000249853; -.
DR   PharmGKB; PA164741639; -.
DR   eggNOG; KOG3704; Eukaryota.
DR   eggNOG; ENOG410XS59; LUCA.
DR   GeneTree; ENSGT00760000119023; -.
DR   HOGENOM; HOG000036663; -.
DR   HOVERGEN; HBG053377; -.
DR   InParanoid; Q8IZT8; -.
DR   KO; K08104; -.
DR   OMA; GRTFNWP; -.
DR   OrthoDB; EOG091G0CS5; -.
DR   PhylomeDB; Q8IZT8; -.
DR   TreeFam; TF350755; -.
DR   Reactome; R-HSA-2022928; HS-GAG biosynthesis.
DR   EvolutionaryTrace; Q8IZT8; -.
DR   GenomeRNAi; 222537; -.
DR   PRO; PR:Q8IZT8; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000249853; -.
DR   CleanEx; HS_HS3ST5; -.
DR   Genevisible; Q8IZT8; HS.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0050656; F:3'-phosphoadenosine 5'-phosphosulfate binding; NAS:UniProtKB.
DR   GO; GO:0008467; F:[heparan sulfate]-glucosamine 3-sulfotransferase 1 activity; IDA:UniProtKB.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; TAS:Reactome.
DR   GO; GO:0015015; P:heparan sulfate proteoglycan biosynthetic process, enzymatic modification; IDA:UniProtKB.
DR   GO; GO:0050819; P:negative regulation of coagulation; IDA:UniProtKB.
DR   GO; GO:0006477; P:protein sulfation; IDA:UniProtKB.
DR   GO; GO:0046596; P:regulation of viral entry into host cell; IDA:UniProtKB.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000863; Sulfotransferase_dom.
DR   Pfam; PF00685; Sulfotransfer_1; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disulfide bond; Glycoprotein;
KW   Golgi apparatus; Membrane; Polymorphism; Reference proteome;
KW   Signal-anchor; Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN         1    346       Heparan sulfate glucosamine 3-O-
FT                                sulfotransferase 5.
FT                                /FTId=PRO_0000085222.
FT   TOPO_DOM      1     12       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     13     32       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     33    346       Lumenal. {ECO:0000255}.
FT   NP_BIND     100    104       PAPS. {ECO:0000250}.
FT   NP_BIND     309    313       PAPS. {ECO:0000250}.
FT   REGION      122    128       Substrate binding. {ECO:0000250}.
FT   REGION      155    158       Substrate binding. {ECO:0000250}.
FT   REGION      226    227       Substrate binding. {ECO:0000250}.
FT   BINDING     183    183       PAPS. {ECO:0000250}.
FT   BINDING     191    191       PAPS. {ECO:0000250}.
FT   BINDING     293    293       PAPS. {ECO:0000250}.
FT   CARBOHYD    287    287       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID    294    304       {ECO:0000250}.
FT   VARIANT     247    247       I -> N (in dbSNP:rs17793043).
FT                                /FTId=VAR_052531.
FT   MUTAGEN      99     99       R->A: Reduces enzyme activity by over
FT                                99%. {ECO:0000269|PubMed:18223645}.
FT   MUTAGEN     104    104       R->A: Reduces enzyme activity by 93%,.
FT                                {ECO:0000269|PubMed:18223645}.
FT   MUTAGEN     155    155       K->A: Reduces enzyme activity by over
FT                                99%. {ECO:0000269|PubMed:18223645}.
FT   MUTAGEN     195    195       Q->A: Reduces enzyme activity by over
FT                                99%. {ECO:0000269|PubMed:18223645}.
FT   MUTAGEN     309    309       K->A: Loss of enzyme activity.
FT                                {ECO:0000269|PubMed:18223645}.
FT   MUTAGEN     311    311       R->A: Reduces enzyme activity by 98%.
FT                                {ECO:0000269|PubMed:18223645}.
FT   STRAND       92     97       {ECO:0000244|PDB:3BD9}.
FT   HELIX       103    110       {ECO:0000244|PDB:3BD9}.
FT   STRAND      116    118       {ECO:0000244|PDB:3BD9}.
FT   HELIX       129    133       {ECO:0000244|PDB:3BD9}.
FT   HELIX       136    140       {ECO:0000244|PDB:3BD9}.
FT   STRAND      151    155       {ECO:0000244|PDB:3BD9}.
FT   HELIX       157    160       {ECO:0000244|PDB:3BD9}.
FT   HELIX       165    172       {ECO:0000244|PDB:3BD9}.
FT   STRAND      177    182       {ECO:0000244|PDB:3BD9}.
FT   HELIX       185    202       {ECO:0000244|PDB:3BD9}.
FT   HELIX       210    214       {ECO:0000244|PDB:3BD9}.
FT   TURN        217    219       {ECO:0000244|PDB:3BD9}.
FT   HELIX       227    231       {ECO:0000244|PDB:3BD9}.
FT   HELIX       234    242       {ECO:0000244|PDB:3BD9}.
FT   HELIX       247    249       {ECO:0000244|PDB:3BD9}.
FT   STRAND      250    254       {ECO:0000244|PDB:3BD9}.
FT   HELIX       255    260       {ECO:0000244|PDB:3BD9}.
FT   HELIX       262    272       {ECO:0000244|PDB:3BD9}.
FT   HELIX       281    283       {ECO:0000244|PDB:3BD9}.
FT   STRAND      284    287       {ECO:0000244|PDB:3BD9}.
FT   TURN        288    291       {ECO:0000244|PDB:3BD9}.
FT   STRAND      292    296       {ECO:0000244|PDB:3BD9}.
FT   STRAND      298    300       {ECO:0000244|PDB:3BD9}.
FT   HELIX       318    339       {ECO:0000244|PDB:3BD9}.
SQ   SEQUENCE   346 AA;  40408 MW;  C763F70793FDB156 CRC64;
     MLFKQQAWLR QKLLVLGSLA VGSLLYLVAR VGSLDRLQPI CPIEGRLGGA RTQAEFPLRA
     LQFKRGLLHE FRKGNASKEQ VRLHDLVQQL PKAIIIGVRK GGTRALLEML NLHPAVVKAS
     QEIHFFDNDE NYGKGIEWYR KKMPFSYPQQ ITIEKSPAYF ITEEVPERIY KMNSSIKLLI
     IVREPTTRAI SDYTQVLEGK ERKNKTYYKF EKLAIDPNTC EVNTKYKAVR TSIYTKHLER
     WLKYFPIEQF HVVDGDRLIT EPLPELQLVE KFLNLPPRIS QYNLYFNATR GFYCLRFNII
     FNKCLAGSKG RIHPEVDPSV ITKLRKFFHP FNQKFYQITG RTLNWP
//
